Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing

26 Aug 2025

Abstract excerpt

Nucleoside reverse transcriptase translocation inhibitors (NRTTIs) are potent antiretroviral agents that block HIV replication. A comprehensive lead optimization campaign was undertaken to develop a novel long-acting NRTTI with the potential for extended-duration dosing for HIV prophylaxis. Broad exploration of nucleoside structure-activity relationship (SAR), leveraging ribose core, periphery, and nucleobase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40857265
DOI: 10.1371/journal.pbio.3003308

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosingPMID 40857265Read ↗

Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.Semantic proximity Read ↗

Small Molecule Drugs Targeting Viral PolymerasesSemantic proximity Read ↗

Discovery of 2,4,5-Trisubstituted 6-Aminopyrimidines as Potent HIV-1 NNRTIs with Improved Resistance Profiles against the K103N/Y181C MutantSemantic proximity Read ↗

Structural and Mechanistic Basis of F227C-Mediated Hypersusceptibility to Islatravir in HIV-1 Reverse TranscriptaseSemantic proximity Read ↗

Preferential remdesivir triphosphate incorporation by SARS-CoV-2 polymerase is altered to ATP by the S759A mutation.Semantic proximity Read ↗

The kinase inhibitor Palbociclib is a potent and specific RNA-binding moleculeSemantic proximity Read ↗

A transient kinetic approach to investigate nucleoside inhibitors of mitochondrial DNA polymerase gamma.Semantic proximity Read ↗

Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.Semantic proximity Read ↗

Remdesivir for the treatment of Covid-19: the value of biochemical studiesSemantic proximity Read ↗

Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different?Semantic proximity Read ↗

Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green MonkeysSemantic proximity Read ↗

Accelerated First-in-Human Clinical Trial of EIDD-2801/MK-4482 (molnupiravir), a Ribonucleoside Analogue with Potent Antiviral Activity Against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.